User menu

Trisenox (R) (arsenic trioxide) in patients with Myelodysplastic syndromes (MDS): Preliminary results of a phase 1/2 study.

Bibliographic reference Vey, N ; Dreyfus, F ; Guerci, A ; Fenaux, P. ; Dombret, H. ; et. al. Trisenox (R) (arsenic trioxide) in patients with Myelodysplastic syndromes (MDS): Preliminary results of a phase 1/2 study..45th Annual Meeting of the American-Society-of-Hematology (SAN DIEGO(California), Dec 06-09, 2003). In: Blood, Vol. 102, no. 11, p. 422A (2003)
Permanent URL http://hdl.handle.net/2078.1/61328